Silvia Mihaela Ilie

Dr. Silvia Mihaela Ilie


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LGLoïck Galland
Loïck Galland
NRNicolas Roussot
Nicolas Roussot
IDIsabelle Desmoulins
Isabelle Desmoulins
DMDidier Mayeur
Didier Mayeur
CKCourèche Kaderbhai
Courèche Kaderbhai
SLSylvain Ladoire
Sylvain Ladoire
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells—such as homologous recombination deficiencies (HRD)—enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors. Different approaches currently exist to analyze impairment of the homologous recombination pathway, e.g., the search for specific mutations in homologous recombination repair (HRR) genes, such as BRCA1/2; the use of genomic scars or mutational signatures; or the development of functional tests. Nevertheless, the role and value of these different tests in breast cancer treatment decisions remains to be clarified. In this review, we summarize current knowledge on the clinical utility of genomic tests, evaluating HRR deficiency for treatment decisions in early and metastatic breast cancer.

16 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LALe Marouille Alexandre
Le Marouille Alexandre
EPEmma Petit
Emma Petit
CKCourèche Kaderbhaï
Courèche Kaderbhaï
IDIsabelle Desmoulins
Isabelle Desmoulins
AHAudrey Hennequin
Audrey Hennequin
ASAntonin Schmitt
Antonin Schmitt
Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A population pharmacokinetic (popPK) model was first constructed to describe palbociclib pharmacokinetic (PK). Individual PK parameters obtained were then used in the pharmacokinetic/pharmacodynamic (PK/PD) model to depict the relation between palbociclib concentrations and absolute neutrophil counts (ANC). The models were built with a population of 143 patients. Palbociclib samples were routinely collected during therapeutic drug monitoring, whereas ANC were retrospectively retrieved from the patient files. The optimal popPK model was a mono-compartmental model with a first-order absorption constant of 0.187 h−1 and an apparent clearance Cl/F of 57.09 L (32.8% of inter individuality variability (IIV)). The apparent volume of distribution (1580 L) and the lag-time (Tlag: 0.658 h) were fixed to values from the literature. An increase in creatinine clearance and a decrease in alkaline phosphatase led to an increase in palbociclib Cl/F. To describe ANC kinetics during treatment, Friberg’s PK/PD model, with linear drug effect, was used. Parameters estimated were Base (2.92 G/L; 29.6% IIV), Slope (0.0011 L/µg; 28.8% IIV), Mean Transit Time (MTT; 5.29 days; 17.9% IIV) and γ (0.102). The only significant covariate was age on the initial ANC (Base), with lower ANC in younger patients. PK/PD model-based simulations show that the higher the estimated CressSS (trough concentration at steady state), the higher the risk of developing neutropenia. In order to present a risk lower than 20% to developing a grade 4 neutropenia, the patient should show an estimated CressSS lower than 100 µg/L.

1 December 2022 in Anticancer Research
Verified
Journal Article
Open access
PDF file
ABAlexandre Beige
Alexandre Beige
FGFrançois Ghiringhelli
François Ghiringhelli
JLJulie Lecuelle
Julie Lecuelle
CTCaroline Truntzer
Caroline Truntzer
GTGilles Truc
Gilles Truc
SISilvia Mihaela Ilie
Silvia Mihaela Ilie
Background/Aim: Bevacizumab and chemotherapy are used in glioblastoma multiforme (GBM) relapse. However, the choice of chemotherapeutic agent remains an open question and this study aimed to evaluate the efficacy and safety of different combinations. Patients and Methods: Between June 2005 and August 2020, all patients treated with chemotherapy plus bevacizumab (BVZ) for recurrent glioblastoma in the Georges-François Leclerc Cancer Center, Dijon, France were included in this retrospective comparative study. The primary objective was progression-free survival (PFS) and as secondary objectives, overall survival (OS), disease control rate (DCR), and safety were investigated. Factors associated with response were also analyzed. Results: A total of 160 patients were screened: 100 received fotemustine plus BVZ (62%) and 62 (38%) received another cytotoxic agent plus BVZ: 35 (22%) irinotecan (IRI), 18 (11%) temozolomide (TEM), and 7 (4%) lomustine (LOM). In the whole population, median PFS was 4.47 months, median OS was 9 months, and 3-month DCR was 51%. Regarding survival according to treatment, median OS was significantly lower in the fotemustine group compared to that in other cytotoxic agents: 7.3 vs. 19.9 months. In the fotemustine group, steroids use at baseline and low Karnofsky performance status were associated with poor median OS. Grade 3-4 adverse events were found in 21.9%, with no difference between groups, but 7 patients had grade 5 adverse events in the fotemustine group. Conclusion: Using real-life data, this study showed lower efficacy of fotemustine and bevacizumab, as compared to IRI or TEM or LOM-BVZ combinations.

24 February 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BRBernard Royer
Bernard Royer
CKCourèche Kaderbhaï
Courèche Kaderbhaï
JFJean-David Fumet
Jean-David Fumet
AHAudrey Hennequin
Audrey Hennequin
IDIsabelle Desmoulins
Isabelle Desmoulins
ASAntonin Schmitt
Antonin Schmitt
Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacokinetics study of palbociclib in women routinely followed in a cancer center. One hundred and fifty-one samples were analyzed. The sampling times after administration ranged from 0.9 to 75 h and the samples were taken between 1 and 21 days after the beginning of the palbociclib cycle. Palbociclib was determined using a validated mass spectrometry method. The best model that described the concentrations was a one-compartment model with first-order absorption and an absorption lag time. Interindividual variability could only be estimated on the clearance and the first-order absorption. Creatinine clearance was found to be a significant covariate for the apparent clearance. No significant covariates could be observed with the first-order absorption. First-order absorption and absorption lag times were difficult to assess because of the constraints linked to the real-world setting due to the small number of samples used during the absorption process. However, palbociclib apparent clearance was satisfactorily estimated. Population pharmacokinetics (POP PK) with palbociclib could help to optimize dosing.

10 January 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SISilvia Mihaela Ilie
Silvia Mihaela Ilie
NBNathalie Briot
Nathalie Briot
GCGuillaume Constatin
Guillaume Constatin
AIAlis Ilie
Alis Ilie
FBFrancoise Beltjens
Francoise Beltjens
LALaurent Arnould
Laurent Arnould
Background: The persistence of residual tumour after neoadjuvant chemotherapy (NAC) in localised triple-negative breast cancer (TNBC) is known to have a negative prognostic value. However, different degrees of expression of some immunohistochemical markers may correlate with different prognoses.Methods: The expression of biomarkers with a known prognostic value, i.e., cytokeratin 5/6 (CK5/6), androgen receptor (AR), epidermal growth factor receptor (EGFR) proliferation-related nuclear antigen Ki-67, human epidermal growth factor receptor 2 (HER2), protein 53 (p53), forkhead box protein 3 (FOXP3), and cluster differentiation 8 (CD8), was analysed by immunohistochemistry in 111 samples after NAC in non-metastatic TNBC patients addressed to Georges-François Leclerc Cancer Centre Dijon, France. Clinical and pathological variables were retrospectively collected. Cox regression was used to identify immunohistochemical (IHC) and clinicopathological predictors of event-free survival (EFS) (relapse or death).Results: Median age was 50.4 years (range 25.6–88.3), 55.9% (n = 62) were non-menopausal, 70 (63.1%) had stage IIA–IIB disease. NAC was mostly sequential anthracycline-taxanes (72.1%), and surgical intervention was principally conservative (51.3%). We found 65.7% ypT1, 47.2% lymph node involvement (ypN+), and 29.4% lymphovascular invasion (LVI). Most residual tumours were EGFR >110 (H-score) (60.5%, n = 66), AR ≥4% (53.2%, n = 58), p53-positive mutated (52.7%, n = 58), CD8 ≥26 (58.1%, n = 61), FOXP3 ≥7 (51.4%, n = 54), more than half in the stroma, and 52.3% (n = 58) HER2 score 0. After a median follow-up of 80.8 months, 48.6% had relapsed. Median EFS was 62.3 months (95% CI, 37.2–not reached (NR)). Factors independently associated with poor EFS were AR-low (p = 0.002), ypN+ (p < 0.001), and LVI (p = 0.001). Factors associated with lower overall survival (OS) were EGFR-low (p = 0.041), Ki-67 high (p = 0.024), and ypN+ (p < 0.001).Conclusion: Post-NAC residual disease in TNBC showed biomarkers specific to a basal-like subtype and markers of lymphocyte infiltration mostly present in the stroma. Prognostic markers for EFS were AR, LVI, and ypN and warrant further validation in a prognostic model.

Verified
Journal Article
Open access
PDF file
AVAlexandru Văcariu
Alexandru Văcariu
SISilvia Mihaela Ilie
Silvia Mihaela Ilie
CVCristin Constantin Vere
Cristin Constantin Vere
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
EMEleni Manthopoulou
Eleni Manthopoulou
Bogdan Silviu UngureanuBogdan Silviu Ungureanu
Bogdan Silviu Ungureanu
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, and reliable prognostic biomarkers are urgently needed to guide risk stratification and treatment. CD74 has been implicated in tumor progression, invasion, and pro-inflammatory signaling in various cancers. This systematic review and meta-analysis aimed to evaluate the association between CD74 expression and key clinicopathological features and survival outcomes in patients with PDAC. A systematic literature search was conducted in PubMed, Web of Science, and Scopus to identify eligible studies reporting on CD74 expression in PDAC tissues (PROSPERO: CRD420261402709). Studies were selected following the PRISMA 2020 guidelines. The methodological quality of the included studies was assessed using the QUIPS tool. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for the associations between CD74 expression and perineural invasion (PNI), lymphatic invasion, lymph node metastasis (pN), vascular permeation, pTNM stage, and overall survival. Statistical analyses were performed using Review Manager v5.4. DerSimonian–Laird random-effects models were applied as sensitivity analysis for every outcome, with Mantel–Haenszel fixed-effects models as the primary analysis according to the level of heterogeneity, which was quantified using the I2 statistic. A total of 83 records were initially identified, of which five studies met the inclusion criteria and were included in the quantitative synthesis. CD74-positive expression was significantly associated with an increased risk of perineural invasion (four cohorts, 351 patients; OR = 3.69; 95% CI: 2.27–5.99; p < 0.00001; I2 = 0%), lymphatic invasion (four cohorts, 351 patients; OR = 2.05; 95% CI: 1.21–3.46; p = 0.007; I2 = 0%), and lymph node metastasis (four cohorts, 462 patients; OR = 1.94; 95% CI: 1.27–2.96; p = 0.002; I2 = 0%). A non-significant trend toward increased vascular permeation (three cohorts, 181 patients; OR = 1.99; 95% CI: 0.84–4.68; p = 0.12; I2 = 0%) and advanced pTNM stage (three cohorts, 284 patients; OR = 1.62; 95% CI: 0.93–2.82; p = 0.09; I2 = 0%) was also observed. Importantly, CD74 positivity was significantly associated with worse overall survival (three cohorts, 293 patients; HR = 2.04, 95% CI: 1.45–2.88; p < 0.00001; I2 = 0%). This analysis was structured into two subgroups: HR = 2.21 (95% CI: 1.50–3.25) in the two cohorts contributing multivariable-adjusted, immunohistochemistry-based estimates, and HR = 1.52 (95% CI: 0.72–3.21) in the single cohort contributing a univariable estimate reconstructed from transcript-level data, with no significant difference between the subgroups (p = 0.38). Because the estimated between-study variance was zero for every outcome, random-effects estimates were almost identical to the fixed-effects estimates throughout. As the pooled survival estimate combines adjusted with unadjusted estimates, it describes a prognostic association rather than established independent prognostic value. This meta-analysis demonstrates that elevated CD74 expression in PDAC is significantly associated with perineural invasion, lymphatic invasion, lymph node metastasis, and poorer overall survival, supporting an association with an adverse prognostic. Because the evidence base comprises few retrospective cohorts that used different, non-standardized thresholds to define CD74 positivity and different definitions of several outcomes, these findings should be regarded as hypothesis-generating: they identify CD74 as a candidate for prospective validation and mechanistic investigation rather than as an established biomarker for risk stratification or therapeutic decision-making. Further large-scale prospective studies are warranted to validate these results and explore the clinical utility of CD74-targeted strategies.